Cancer Archives

News and Trends 8 Nov 2022

Telix Pharmaceuticals sees positive results in kidney cancer imaging study

Telix Pharmaceuticals Limited said it has highly positive top-line results from its pivotal phase III study of its investigational renal (kidney) cancer positron emission tomography (PET) imaging agent, TLX250-CDx (89 Zr- DFO-girentuximab). The ZIRCON study (Zirconium in Renal Cancer Oncology, NCT03849118) has met its co-primary and secondary endpoints. The study results delivered 86% sensitivity and […]

November 8, 2022 - 3 minutesmins - By Jim Cornall

AKT inhibitor ipatasertib shows signs of effectiveness in patient trial

News and Trends 7 Nov 2022

Scancell in-licenses Vaccitech’s SNAPvax tech for cancer study

Scancell Holdings plc, a developer of immunotherapies, today (November 7) announced it has in-licensed the SNAPvax technology from Vaccitech plc, a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapies and vaccines. The agreement will allow Scancell to formulate and manufacture Modi-2, with the aim of initiating a phase 1 clinical study […]

November 7, 2022 - 3 minutesmins - By Liza Laws

News and Trends 7 Nov 2022

First patient dose completed for bladder cancer diagnostic drug

Asieris Pharmaceuticals says it has completed the first patient dose in its phase III bridging trial for Hexvix, a drug used for the diagnosis of bladder cancer. Asieris Pharmaceuticals is a global biopharmaceutical company specializing in the discovery and development of drugs for the treatment of genitourinary tumors and other major diseases. The study is a […]

November 7, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 3 Nov 2022

Positive results of cancer treatment to be presented at Boston conference

Results of a cancer treatment in the treatment of gynecologic and breast cancer are to be presented next week, November 8-12, at the Society for Immunotherapy of Cancer (SITC) conference in Boston. Alderaan Biotechnology is a preclinical biotech company that focuses on monoclonal antibody development. It will be making announcements about the most recent development […]

November 3, 2022 - 2 minutesmins - By Liza Laws

News and Trends 3 Nov 2022

Senescent cells as vaccines against cancer?

Cancer cells have a series of features that allow the immune system to identify and attack them. However, these same cells create an environment that blocks immune cells and protects the tumor. This means immune cells cannot reach the cancer cells to remove them. The scientific community has been working to increase the effectiveness of […]

November 3, 2022 - 5 minutesmins - By Jim Cornall

News and Trends 2 Nov 2022

Authorization given to BeiGene’s chemo-free treatment option for lymphoma

Marketing authorization has been granted to a drug to treat relapsed/refractory (R/R) marginal zone lymphoma (MZL) without chemotherapy, it was announced today (November 2). The European Commission (EC) gave the authorization to biotech company, BeiGene, for Brukinsa (zanubrutinib), which treats adults with the condition who have received at least one prior anti-CD20-based therapy. The approval […]

November 2, 2022 - 3 minutesmins - By Liza Laws

Startup Scout 2 Nov 2022

Breakpoint Therapeutics sabotages DNA repair in cancer cells

The Hamburg-based Evotec spinout Breakpoint Therapeutics is working on cancer treatments that block the ability of tumor cells to repair their own DNA. In the last decade, a new class of drugs known as DNA damage response (DDR) inhibitors has risen to prominence in the oncology space. These drugs are able to break down the […]

November 2, 2022 - 4 minutesmins - By Jonathan Smith

News and Trends 2 Nov 2022

CV6 Therapeutics raises $9.2M to test cancer drug

CV6 Therapeutics has secured $9.2m to progress its lead oncology asset, CV6-168, into a first-in-human phase 1a clinical trial and perform further scientific development work. CV6 Therapeutics is a drug development biotechnology company specializing in innovative small molecule therapeutics for cancer and inflammatory diseases. Investors participating in the financing include QUBIS, the commercialization arm of […]

November 2, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 2 Nov 2022

Alkermes to separate oncology business

Alkermes plc is to explore separating its commercial-stage neuroscience business and development-stage oncology business. The company, its board and external financial and legal advisors plan to explore a separation of the oncology business into an independent, publicly-traded company (Oncology Co.) as part of an ongoing review of strategic alternatives for the oncology business. Alkermes said […]

November 2, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 2 Nov 2022

New therapeutic strategy to improve treatment of aggressive endometrial cancer

Endometrial cancer (EC) is the most common type of gynecological cancer and is the fourth most common type of tumor in women in developed countries. Although it has a good prognosis if detected early, advanced and aggressive cases have a high mortality rate and are often resistant to standard chemotherapy treatments. Now, a study published […]

November 2, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 2 Nov 2022

Could DNA nanotransporters treat cancer?

A team of Canadian researchers from Université de Montréal has designed and validated a new class of drug transporters made of DNA 20,000 times smaller than a human hair. The DNA nanotransporters could improve how cancers and other diseases are treated. Reported in a new study in Nature Communications, the molecular transporters can be chemically […]

November 2, 2022 - 4 minutesmins - By Jim Cornall

Anastasiia Slynko biotech investment october 2022

In Depth 1 Nov 2022

The biggest private biotech investments in October 2022

The companies Tempus Labs, Oculis and VectorBuilder Biotechnology bagged the biggest biotech investments in October 2022. Oncology and biomanufacturing research attracted the biggest funding rounds. We’re heading for the beginning of winter in the Northern Hemisphere, and biotech fundraising is still ticking away despite adverse market conditions. We’ve gathered the biggest biotech investments that went […]

November 1, 2022 - 3 minutesmins - By Jonathan Smith

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Cancer

Telix Pharmaceuticals sees positive results in kidney cancer imaging study

Scancell in-licenses Vaccitech’s SNAPvax tech for cancer study

First patient dose completed for bladder cancer diagnostic drug

Positive results of cancer treatment to be presented at Boston conference

Senescent cells as vaccines against cancer?

Authorization given to BeiGene’s chemo-free treatment option for lymphoma

Breakpoint Therapeutics sabotages DNA repair in cancer cells

CV6 Therapeutics raises $9.2M to test cancer drug

Alkermes to separate oncology business

New therapeutic strategy to improve treatment of aggressive endometrial cancer

Could DNA nanotransporters treat cancer?

The biggest private biotech investments in October 2022

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!